AskBio Declares Independence After Bayer Acquisition
Will Not Be Hamstrung By Bureaucracy
Executive Summary
The gene therapy specialist's CEO Sheila Mikhail tells Scrip she is excited to be getting access to the German group's late-stage clinical and operational expertise while keeping AskBio's entrepreneurial culture and carrying on as an autonomous company on an arm’s-length basis.
You may also be interested in...
BIO 2021 Notebook: Going Fast And Being Precise
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.
BIO 2021 Notebook: Going Fast And Being Precise
News and views from day three of the BIO Digital annual meeting include Amgen’s CEO on speedy development and NIH’s chief on bringing personalized medicine to COVID vaccines.
Big Pharma Switch Pitch To Attract Cash-Rich Biotechs
With the biotech sector awash with public and private capital, companies can carry on longer without needing to link up with a bigger player. Big pharma C-suite leaders have been discussing how their firms sweeten potential deals at BIO Digital.